WallStSmart

IQVIA Holdings Inc (IQV)vsWaters Corporation (WAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 350% more annual revenue ($16.98B vs $3.77B). WAT leads profitability with a 11.9% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.98. IQV earns a higher WallStSmart Score of 55/100 (C).

IQV

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.7Quality: 3.0
Piotroski: 2/9Altman Z: 1.23

WAT

Buy

50

out of 100

Grade: C-

Growth: 5.3Profit: 5.0Value: 3.3Quality: 7.0
Piotroski: 2/9Altman Z: 4.85
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+11.9%)

Margin of Safety

+11.9%

Fair Value

$201.09

Current Price

$228.20

$27.11 discount

UndervaluedFair: $201.09Overvalued
WATSignificantly Overvalued (-81.9%)

Margin of Safety

-81.9%

Fair Value

$180.97

Current Price

$396.08

$215.11 premium

UndervaluedFair: $180.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.988/10

Growing faster than its price suggests

WAT3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
91.4%10/10

Revenue surging 91.4% year-over-year

Altman Z-ScoreHealth
4.8510/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

IQV4 concerns · Avg: 2.8/10
P/E RatioValuation
29.2x4/10

Moderate valuation

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-0.6%2/10

Earnings declined 0.6%

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

WAT4 concerns · Avg: 3.3/10
PEG RatioValuation
1.694/10

Expensive relative to growth rate

Return on EquityProfitability
2.9%3/10

ROE of 2.9% — below average capital efficiency

Operating MarginProfitability
2.8%3/10

Operating margin of 2.8%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.98 suggests the stock is reasonably priced for its growth.

Bull Case : WAT

The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 91.4% demonstrates continued momentum.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.58 is elevated, increasing financial risk.

Bear Case : WAT

The primary concerns for WAT are PEG Ratio, Return on Equity, Operating Margin. A P/E of 48.1x leaves little room for execution misses.

Key Dynamics to Monitor

IQV profiles as a value stock while WAT is a growth play — different risk/reward profiles.

WAT carries more volatility with a beta of 1.20 — expect wider price swings.

WAT is growing revenue faster at 91.4% — sustainability is the question.

IQV generates stronger free cash flow (491M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (55/100 vs 50/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Waters Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Want to dig deeper into these stocks?